Anthropic’s takes on drug discovery with Claude |
![]() |
| Anthropic is going all-in on the $2 trillion biotech market. |
| On Monday, the AI safety and research startup launched Claude for Life Sciences, a new capability designed to support scientists working on drug discovery: one of the most complex and costly processes in research, CNBC reported. |
| Part of the Claude model family, the tool is built to automate time-consuming tasks like hypothesis generation, literature review and regulatory drafting. The goal is to reduce the busywork that slows down early-stage research and development and, in turn, ship potentially life saving treatments to market faster. |
| It’s a timely, and arguably Anthropic’s most practical use of AI yet. Developing a single drug can take 10 to 15 years and cost $2.6 billion. Claude isn’t running lab experiments or clinical trials, but with its new feature, Anthropic believes it can streamline the paperwork and data handling that often bog down progress. |
| “We want a meaningful percentage of all life-science work in the world to run on Claude,” Eric Kauderer-Abrams, head of Anthropic’s biology and life sciences division, told CNBC. |
| The launch comes two months after Anthropic hired Kauderer-Abrams to lead its biology and life science division. Since then, Anthropic has partnered with platforms like Benchling, which manages lab data for over 200,000 researchers, and 10x Genomics, known for its genomic sequencing tools, to integrate their tools into Claude. |
| In a demo shared with CNBC, a scientist used Claude to query experimental data in Benchling, generate summary tables, and compile a report — cutting a multi-day process down to minutes. |
| Anthropic isn’t alone in targeting the drug discovery space. Last week, Google DeepMind released Cell2Sentence-Scale 27B, a model developed with Yale to help uncover cancer cell behaviors. OpenAI, as well as startups like Recursion and Cradle, are also using AI to analyze proteins and extract insights from lab data. |
| Kauderer-Abrams is under no illusions that Claude will solve biology’s hardest problems overnight. But he sees it as a tool that could give scientists a faster path to the next big breakthrough. |
-
Archives
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- January 2015
-
Meta
